Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR, Rivera F, Im SA, Bodoky G, Salazar R, Maindrault-Goebel F, Shacham-Shmueli E, Bajetta E, Makrutzki M, Shang A, André T, Hoff PM. de Gramont A, et al. Among authors: maindrault goebel f. Lancet Oncol. 2012 Dec;13(12):1225-33. doi: 10.1016/S1470-2045(12)70509-0. Epub 2012 Nov 16. Lancet Oncol. 2012. PMID: 23168362 Clinical Trial.
First-line therapy for advanced colorectal cancer.
de Gramont A, Tournigand C, Louvet C, Maindrault-Goebel F, André T. de Gramont A, et al. Curr Oncol Rep. 2005 May;7(3):167-72. doi: 10.1007/s11912-005-0069-y. Curr Oncol Rep. 2005. PMID: 15847706 Review.
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, André T, Bennamoun M, Mabro M, Artru P, Carola E, Flesch M, Dupuis O, Colin P, Larsen AK, Afchain P, Tournigand C, Louvet C, de Gramont A. Chibaudel B, et al. Among authors: maindrault goebel f. J Clin Oncol. 2009 Dec 1;27(34):5727-33. doi: 10.1200/JCO.2009.23.4344. Epub 2009 Sep 28. J Clin Oncol. 2009. PMID: 19786657 Clinical Trial.
Platinum-sensitivity in metastatic colorectal cancer: towards a definition.
Chibaudel B, Tournigand C, Bonnetain F, Maindrault-Goebel F, Lledo G, André T, Larsen AK, Bengrine-Lefevre L, Louvet C, de Gramont A. Chibaudel B, et al. Among authors: maindrault goebel f. Eur J Cancer. 2013 Dec;49(18):3813-20. doi: 10.1016/j.ejca.2013.07.150. Epub 2013 Sep 3. Eur J Cancer. 2013. PMID: 24011937
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).
Maindrault-Goebel F, de Gramont A, Louvet C, André T, Carola E, Gilles V, Lotz JP, Tournigand C, Mabro M, Molitor JL, Artru P, Izrael V, Krulik M. Maindrault-Goebel F, et al. Ann Oncol. 2000 Nov;11(11):1477-83. doi: 10.1023/a:1026520812351. Ann Oncol. 2000. PMID: 11142489 Free article. Clinical Trial.
High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).
Maindrault-Goebel F, de Gramont A, Louvet C, André T, Carola E, Mabro M, Artru P, Gilles V, Lotz JP, Izrael V, Krulik M; Oncology Multidisciplinary Research Group (GERCOR). Maindrault-Goebel F, et al. Eur J Cancer. 2001 May;37(8):1000-5. doi: 10.1016/s0959-8049(01)00068-5. Eur J Cancer. 2001. PMID: 11334725 Clinical Trial.
25 results